Search

Your search keyword '"Graupera, Isabel"' showing total 493 results

Search Constraints

Start Over You searched for: Author "Graupera, Isabel" Remove constraint Author: "Graupera, Isabel"
493 results on '"Graupera, Isabel"'

Search Results

2. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD

3. Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

4. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis

6. Alcoholic Foamy Degeneration, an Entity Resembling Alcohol-Associated Hepatitis: Diagnosis, Prognosis, and Molecular Profiling

7. Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

10. Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease

11. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

12. A global research priority agenda to advance public health responses to fatty liver disease

13. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease

14. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

15. Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas»

17. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population

18. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

19. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease

22. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

23. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

24. WED-155 A ratio of exchangeable copper below 15% accurately excludes Wilson disease and may be useful for the first-line ethiologic work-up within a liver unit

26. OS-059 Unveiling Socioeconomic Disparities on Liver Disease: A Comparative Study of ALD, MASLD, and MetALD Patients

27. TOP-241-YI Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5, 517 participants

28. FRI-211 The presence of autoimmune characteristics in metabolic associated steatosis liver disease patients increases the risk of liver disease progression. Study from the multicentric spanish register (HEPAMET)

29. WED-284-YI The Fatty Liver Index (FLI) is more accurate than FIB-4 for detection of advanced liver fibrosis in patients with type-2 Diabetes Mellitus (T2DM) in Primary Care

30. FRI-219-YI Recompensation and liver function improvement in patients with decompensated cirrhosis due to metabolic-dysfunction associated steatotic liver disease (MASLD): a retrospective cohort study

31. THU-056 Soluble PD-L1 levels as predictors of ACLF in decompensated cirrhosis: findings from two independent cohorts

32. OS-005-YI Single-cell RNA sequencing analysis in alcohol-related liver disease identifies specific cell subpopulations characterized by an inflammatory profile in alcohol-associated hepatitis

33. WED-055 Effect of long-term treatment with Simvastatin and Rifaximin in mitochondrial and proinflammatory pathways in patients with decompensated cirrhosis. A single-cell RNA seq analysis in PBMCs

36. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis

37. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

40. Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis

41. LiverPRO for the Prediction of Significant Liver Fibrosis in Primary Care: Development, Validation, and Prognostic Evaluation of a Novel Score

42. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia

43. Screening for fibrosis promotes life-style changes. A prospective cohort study in 4,796 individuals

44. Clinical epidemiology of non-alcoholic fatty liver disease in children and adolescents. The LiverKids: Study protocol

45. Position paper of the Catalan Society of Gastroenterology about hepatic elastography 2022

46. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial

47. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study

48. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

50. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure

Catalog

Books, media, physical & digital resources